Skrzeplina w lewym przedsionku po krótkotrwałym przerwaniu leczenia riwaroksabanem by Buksińska-Lisik, Małgorzata Ewa et al.
www.journals.viamedica.pl/folia_cardiologica
Folia Cardiologica 2018 
tom 13, nr 5, strony 453–455 
DOI: 10.5603/FC.a2018.0086 
Copyright © 2018 Via Medica
ISSN 2353–7752
PRACA KAZUISTYCZNA
453
Address for correspondence: dr n. med. Małgorzata Ewa Buksińska-Lisik, III Klinika Chorób Wewnętrznych i Kardiologii,  
Warszawski Uniwersytet Medyczny, ul. Lindleya 4, 02–005 Warszawa, Poland, e-mail: mblisik@wp.pl
Thrombus in the left atrium after brief interruption  
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Abstract
Planning an invasive procedure with a high risk of bleeding is the most common reason for temporary interruptions of 
anticoagulant therapy in patients with atrial fibrillation. Bridging therapy is strongly recommended only in patients with 
mechanical heart valves. This case report presents a 75-year-old patient with ischaemic stroke and left atrial thrombus 
that occurred after a short treatment interruption with rivaroxaban without bridging therapy in a patient with ‘nonval-
vular’ atrial fibrillation.
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Introduction
The role of non-vitamin K antagonist oral anticoagulants in 
lowering the risk of embolic complications in ‘nonvalvular’ 
atrial fibrillation (AF) is well known. In the case of planned 
invasive procedures with a high bleeding risk, anticoagu-
lation therapy should be temporarily interrupted. 
According to AHA/ACC/HRS guidelines, for patients wit-
hout mechanical heart valves, bridging therapy decisions 
should balance stroke and bleeding risks and the length 
of time during which a patient will not be anticoagulated 
[1]. However, according to ESC guidelines, bridging therapy 
is recommended only for patients with prosthetic heart 
valves and does not seem to be beneficial in patients 
without mechanical heart valves [2]. 
Herein, we report a case of fast thrombus formation 
in the left atrium and ischaemic stroke that occurred af-
ter brief discontinuation of rivaroxaban in a patient with 
‘nonvalvular’ AF.
Case report
A 75-year-old man with a history of mitral valve repair in 
2012 (annuloplasty and the implantation of artificial cords) 
and permanent AF was admitted to the Orthopaedic 
Department due to planned total hip arthroplasty. His 
thromboembolic risk according to the CHA2DS2-VASc score 
was 3. The patient had been treated with warfarin in the 
past, but in 2014 he was switched to rivaroxaban and was 
complaining with all his medications. He had regular follow 
ups with his cardiologist, and a transthoracic echocardio-
gram (TTE) carried out three months earlier did not reveal 
any clot in the left atrium. On admission to the Orthopedic 
Department he was in good condition. The bleeding risk in 
total hip replacement surgery was high, so rivaroxaban was 
discontinued. After 48 hours the patient suffered a stroke, 
manifesting left upper and lower extremity hemiparesis 
and aphasia. Computed tomography revealed an ischae-
mic stroke from a large left middle cerebral artery (MCA). 
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After admission to the Neurology Department, the patient’s 
neurological condition improved with increased left-side 
strength and a regained ability to communicate simply. 
He was not a candidate for thrombolysis, mainly because 
of the time delay. Three days later, the patient underwent 
a TTE which demonstrated mild to moderate mitral regur-
gitation and a large, immobile thrombus in the significantly 
enlarged left atrium (Figure 1). Enoxaparin 1 mg/kg sc two 
times a day was started, followed by warfarin. After seven 
days on the therapy, TTE showed a decreased thrombus 
size (Figure 2).
Discussion
In clinical practice, temporary interruptions of anticoagu-
lation (TI) are common in patients with AF. TI is associated 
with an increased risk of embolic events, which is similar 
with rivaroxaban or warfarin, and significantly higher after 
three or more days of discontinuation [3]. The use of brid-
ging therapy does not affect stroke/systemic embolism 
rates during TIs [4]. Moreover, the use of bridging anti-
coagulation is significantly associated with higher overall 
bleeding and adverse event rates [5].
In the presented case, stroke occurred exactly 48 ho-
urs after rivaroxaban interruption with documented fast 
thrombus formation in the LA. Given the result of the pre-
vious TTE and the rapid treatment effect of low molecular 
weight heparin, it seems very unlikely that the thrombus was 
‘old’. It is much more likely that it was a result of rivaroxaban 
discontinuation. Probably, the effect of mitral annuloplasty 
and huge atrium size may lead to local blood slow flow, 
resulting in the easy formation of a thrombus. Watanabe 
et al. found a few echocardiographic parameters including 
left atrial dimension that would predict warfarin-resistant LA 
thrombus formation [6]. Furthermore, Kim et al. [7] found 
that adding LA functional markers to the clinical risk factors 
can improve the predictive value of the CHA2DS2-VASc score.
All these findings suggest that structural changes and 
remodelling of LA should receive greater consideration 
when assessing embolic risk in AF.
Conclusions
This case suggests that patients with AF after mitral valve 
repair need more attention to determine the best peri-
operative strategy when stopping anticoagulation therapy.
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Figure 1. Transthoracic echocardiogram (TTE) — remarkably enlar-
ged left atrium and a large thrombus (23 × 21 mm)
Figure 2. Transthoracic echocardiogram (TTE) after seven 
days of anticoagulation therapy — a decrease in thrombus size 
(12 × 9 mm)
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Streszczenie
Planowanie procedury inwazyjnej o wysokim ryzyku krwawienia stanowi najczęstszą przyczynę czasowego przerwania 
leczenia przeciwzakrzepowego u pacjentów z migotaniem przedsionków (AF). Terapia pomostowa jest zdecydowanie 
zalecana jedynie u pacjentów z mechanicznymi zastawkami serca. W opisie przypadku przedstawiono 75-letniego 
pacjenta z udarem niedokrwiennym mózgu i skrzepliną w lewym przedsionku, które wystąpiły po krótkim przerwaniu 
leczenia riwaroksabanem bez zastosowania leczenia pomostowego u pacjenta z „niezastawkowym” AF.
Słowa kluczowe: skrzeplina w lewym przedsionku, migotanie przedsionków, udar niedokrwienny, riwaroksaban
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